Product screening
Antibodies
Proteins
FAS-L Polyclonal Antibody
Alias:Tumor necrosis factor ligand superfamily member 6;Apoptosis antigen ligand;APTL;CD95 ligand;CD95-L;Fas antigen ligand;Fas ligand;FasL;CD antigen CD178;[Cleaved into: Tumor necrosis factor ligand superfamily member 6, membrane form;Tumor necrosis factor ligand superfamily member 6, soluble form;Receptor-binding FasL ectodomain;Soluble Fas ligand;sFasL;ADAM10-processed FasL form;APL;FasL intracellular domain;FasL ICD;SPPL2A-processed FasL form;SPA;]
Specifications
50μL;100μL
Delivery date
Spot
Target
FAS-L
Reactivity
Human,Rat,Mouse,
Application - After Update
IHC,IF,ELISA
Host Species
Rabbit
Isotype
IgG
Modify
Unmodified
Recommended dilution ratio
IHC 1:50-200;ELISA 1:10000-20000;IF 1:50-200
compose
Liquid in PBS containing 50％ glycerol, 0.5％ BSA and 0.02％ sodium azide.
Store
-15°C to -25°C/1 year（Do not lower than -25°C）
Soncentration
1 mg/ml
Clonality
Polyclonal
Immunogen
Synthetic peptide from human protein at AA range: 121-170
Specificity
The antibody detects endogenous FAS-L
Gene name
FASLG APT1LG1 CD95L FASL TNFSF6
Protein name
Tumor necrosis factor ligand superfamily member 6 （Apoptosis antigen ligand） （APTL） （CD95 ligand） （CD95-L） （Fas antigen ligand） （Fas ligand） （FasL） （CD antigen CD178） [Cleaved into: Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis factor ligand superfamily member 6, soluble form （Receptor-binding FasL ectodomain） （Soluble Fas ligand） （sFasL）; ADAM10-processed FasL form （APL）; FasL intracellular domain （FasL ICD） （SPPL2A-processed FasL form） （SPA）]
Organism-1
Human